Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of SYN 115 as Adjunctive Therapy in Levodopa-treated Parkinson's Subjects With End of Dose Wearing Off

Next Previous
Trial Profile

A Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of SYN 115 as Adjunctive Therapy in Levodopa-treated Parkinson's Subjects With End of Dose Wearing Off

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tozadenant (Primary) ; Levodopa
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Biotie Therapies Corp.; UCB

    • Most Recent Events

    • 08 Jun 2017 Results of a post-hoc analysis from this trial presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
    • 19 Jan 2016 Results published in an Acorda Therapeutics media release.
    • 20 Feb 2015 According to Biotie Therapies media release, it expects that the Phase 2b study will be considered the first of two pivotal studies required for registration for tozadenant in PD patients with end-of-dose 'wearing-off'.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top